Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION22(8) · pp.1455 · 2016
- 피인용
- Web of Science 18
- JCR IF
- JCR 2015 3.98
- ISSN
- 1083-8791
저자
- Kang, Hyoung Jin제1저자Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
- Hong, Kyung TaekDepartment of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
- Lee, Ji WonDepartment of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
- Kim, HyeryDepartment of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
- Park, Kyung DukDepartment of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
- Shin, Hee YoungDepartment of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
- Lee, Soo HyunDepartment of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
- Yoo, Keon HeeDepartment of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
- Sung, Ki WoongDepartment of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
- Koo, Hong HoeDepartment of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
- Lee, Jae WookDepartment of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, South Korea
- Chung, Nak GyunDepartment of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, South Korea
- Cho, BinDepartment of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, South Korea
- Kim, Hack KiDepartment of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, South Korea
- Koh, Kyung NamDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
- Im, Ho JoonDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
- Seo, Jong JinDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
- Jung, Hyun JooDepartment of Pediatrics, Ajou University School of Medicine, Suwon, South Korea
- Park, Jun EunDepartment of Pediatrics, Ajou University School of Medicine, Suwon, South Korea
- Lee, Young HoDepartment of Pediatrics, Hanyang University College of Medicine, Seoul, South Korea
- 임영탁Department of Pediatrics, Pusan National University School of Medicine, Pusan, South Korea
- Lim, Yeon JungDepartment of Pediatrics, Chungnam National University College of Medicine, Daejeon, South Korea
- Kim, Sun YoungDepartment of Pediatrics, Chungnam National University College of Medicine, Daejeon, South Korea
- Yoo, Eun SunDepartment of Pediatrics, Ewha Woman's University School of Medicine, Seoul, South Korea
- Ryu, Kyung HaDepartment of Pediatrics, Ewha Woman's University School of Medicine, Seoul, South Korea
- Lee, Jae HeeDepartment of Pediatrics, Chung-Ang University Hospital, Seoul, South Korea
- Park, Jeong-ADepartment of Pediatrics, Inje University Haeundae Paik Hospital, Pusan, South Korea
- Park, Sang KyuDepartment of Pediatrics, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea
- Ahn, Hyo Seop교신저자Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
초록
Hematopoietic stem cell transplantation (HSCT) is a curative therapy for severe aplastic anemia (SAA); however, the optimal conditioning regimen for HSCT with an unrelated donor has not yet been defined. A previous study using a fludarabine (FLU), cyclophosphamide (Cy), and antithymocyte globulin (ATG) conditioning regimen (study A: 50 mg/kg Cy once daily i.v. on days -9, -8, -7, and -6; 30 mg/m(2) FLU once daily i.v. on days -5, -4, -3, and -2; and 2.5 mg/kg of ATG once daily i.v. on days -3, -2, and -1) demonstrated successful engraftment (100%) but had a high treatment-related mortality rate (32.1%). Therefore, given that Cy is more toxic than FLU, we performed a new phase II prospective study with a reduced-toxicity regimen (study B: 60 mg/kg Cy once daily i.v. on days -8 and -7; 40 mg/m(2) FLU once daily i.v. on days -6, -5, -4, -3, and -2; and 2.5 mg/kg ATG once daily i.v. on 3 days). Fifty-seven patients were enrolled in studies A (n = 28) and B (n = 29), and donor type hematologic recovery was achieved in all patients in both studies. The overall survival (OS) and event-free survival (EFS) rates of patients in study B was markedly improved compared with those in study A (OS: 96.7% versus 67.9%, respectively, P =.004; EFS: 93.3% versus 64.3%, respectively, P =.008). These data show that a reduced-toxicity conditioning regimen with FLU, Cy, and ATG may be an optimal regimen for SAA patients receiving unrelated donor HSCT. (C) 2016 American Society for Blood and Marrow Transplantation.
키워드
Severe aplastic anemiaUnrelated donorFludarabineCyclophosphamideThymoglobulinAntithymocyte globulin (ATG)STEM-CELL TRANSPLANTATIONVERSUS-HOST-DISEASEMARROW TRANSPLANTATIONIMMUNOSUPPRESSIVE THERAPYCHILDRENFAILURETHYMOGLOBULINIRRADIATIONATG
식별자
- WoS UID
- 000380417400017



로그인
연구물 목록으로